$INO 2/12 finished enrollment: U.S. NIH Grant/Contract PENNVAX-GP, INO-6145, INO-9012, CELLECTRA® 2000 Therapeutic Vaccination in Treated HIV Disease at UCLA, UCSF P1/2 Status: Active, not recruiting. Enrollment: 56 [Actual]. Other Study ID Numbers: DAIDS-ES 38409 U01AI131296 ( U.S. NIH Grant/Contract ) Estimated Primary Completion Date : December 1, 2021 Sponsors and Collaborators National Institute of Allergy and Infectious Diseases (NIAID) University of California, Los Angeles Inovio Pharmaceuticals Study Officials: Steven Deeks, MD Principal Investigator University of California, San Francisco clinicaltrials.gov/ct2/hist... Our program is inspired by the recent success of VGX-3100 (Inovio), a DNA therapeutic vaccine for HPV that leads to histopathologic regression of pre-malignant lesions in people and is associated with a potent, sustained boost to HPV-specific CD8+ T cell populations.